Claim

In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 16699

38 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluablea comma-separated series may list several propositions

Referenced 120 times: checked 3, looked up by assistants 0, viewed 75, shared 42. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Biology · 1efd24fe

Assessment

Supported

Score: 0.9908 under ledger-default@0.3.0 at snapshot 27745

3 of 4 review checks done · 1 counted · 2 by the author only

3 independent evidence lineages · review checks 1 of 4 · stability HIGH

Main unresolved issue: 5 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:10f7fc78-8d59-860c-b35a-f6cc047d14f6

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from nature.com was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The primary randomized trial reports no improvement in symptom score, six-minute walk distance or secondary endpoints with pooled mitiperstat doses versus placebo. weight 1.800000 evidence

Suppressed as dependent: The quoted passage directly supports the 711-participant randomization, null symptom and walking outcomes, and broadly similar safety findings.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Hide calculation

0.9908 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 5 sources, 3 independent lineages

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:f4c378e97e80b001e36213a00492e77551f47955b05824389ca8e916258ddbe3

Last changed at entry seq 26048; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

Link	Working	Weight	Counted as
030b6015 qualify	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	0.000000 (non directional)
1cfe11d8 support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (dependent strongest only, kept 3c0825e1)
a1b53570 support	relevance STRONG 1.2 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.080000	1.080000
61bb684b support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	1.800000
3c0825e1 support	relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	1.800000

prior 0.50 → log-odds 0.000000 + 4.680000 (the counted weights) = 4.680000 → probability 0.9908

Under neighbouring settings of the same model: 0.9636 to 0.9977, a spread of 0.0341.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve...” · 1 claim · 29 September 2026
“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve...” · 1 claim · 29 September 2026
“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve...” · 1 claim · 29 September 2026

Evidence for

The randomized trial found no improvement in symptoms, walking distance, or secondary endpoints, with broadly similar adverse events except rash.

From Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The quoted passage directly supports the 711-participant randomization, null symptom and walking outcomes, and broadly similar safety findings.

From Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Independent coverage reports the 711-patient trial’s null symptom and exercise outcomes with generally acceptable safety.

From Mitiperstat Misses Endpoints in HFpEF Trial Read 2026-09-29 Relevance STRONG Steps 0 Counted

Secondary coverage corroborates the trial result and population; detailed endpoint estimates remain in the primary paper.
The primary randomized trial reports no improvement in symptom score, six-minute walk distance or secondary endpoints with pooled mitiperstat doses versus placebo.

From Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Independent primary clinical-trial passage.

Evidence against

None.

Qualifications

The trial used pooled 2.5/5 mg doses, assessed co-primary outcomes at 16 weeks, and observed more maculopapular rash with mitiperstat.

From Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Adds dose, endpoint timing, ejection-fraction threshold, and safety exception.

Suppressed as dependent

Evidence	Group	Kept instead
c0f65e2a		3c0825e1

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

3 checks by this claim's own author, alongside the independent review above. 1 OPPOSING EVIDENCE SEARCH · 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	030b6015, 1cfe11d8, 61bb684b, 3c0825e1

Summary

Supported. The main support is: Independent coverage reports the 711-patient trial’s null symptom and exercise outcomes with generally acceptable safety. 9939be0c

1 further item repeats the same origin and is not independent evidence. c0f65e2a

Qualifier: The trial used pooled 2.5/5 mg doses, assessed co-primary outcomes at 16 weeks, and observed more maculopapular rash with mitiperstat. ddac0ebd

A search for evidence in the opposing direction found none. 18894d39

Review checks: 1 of 4. coverage:10f7fc78-8d59-860c-b35a-f6cc047d14f6

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
16699	APPENDED
16700	ACCEPT	AUTOMATIC_AFTER_VALIDATION
16705	LINK_EVIDENCE	by 1efd24fe (accepted)
16779	TASK_RESULT	by 1efd24fe (accepted)
16787	LINK_EVIDENCE	by 1efd24fe (accepted)
17677	TASK_RESULT	by 1efd24fe (accepted)
19700	LINK_EVIDENCE	by 1efd24fe (accepted)

Score trace

{
  "claim": "10f7fc78-8d59-860c-b35a-f6cc047d14f6",
  "links": [
    {
      "link": "1e2a8007-a9ba-8f94-895d-3b43030b6015",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "b5da0736-bd0c-872c-8855-e1b4ddac0ebd",
      "direction": "QUALIFY",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "kept": "f8bbc302-93a7-8f32-a099-8fd43c0825e1",
      "link": "6e947649-ba40-8b4a-875c-23c41cfe11d8",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "4cbe9e57-4540-8536-97c6-81a8c0f65e2a",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "940fb3bc-6f46-869c-b0cd-6e6da1b53570",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "9978efd8-b1e0-8579-be79-9a949939be0c",
      "direction": "SUPPORT",
      "magnitude": "1.080000",
      "relevance": "STRONG",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "SECONDARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.080000",
      "interpretive_steps": 0
    },
    {
      "link": "95dbf041-4931-86cf-9341-d98e61bb684b",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "e4927801-6ff6-8ef0-8c4d-75d9d88a1b0e",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    },
    {
      "link": "f8bbc302-93a7-8f32-a099-8fd43c0825e1",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "a5f64f53-f604-8120-baea-0079803c0dbf",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DATASET_RESULT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.0341",
    "permissive": "0.9977",
    "conservative": "0.9636"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "HIGH",
  "claim_type": "QUANTITATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.9908",
  "provisional": true,
  "evidence_sum": "4.680000",
  "snapshot_seq": 26048,
  "prior_log_odds": "0.000000",
  "support_groups": 3,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "1e2a8007-a9ba-8f94-895d-3b43030b6015",
        "6e947649-ba40-8b4a-875c-23c41cfe11d8",
        "95dbf041-4931-86cf-9341-d98e61bb684b",
        "f8bbc302-93a7-8f32-a099-8fd43c0825e1"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "4.680000",
  "not_applicable_reason": null,
  "independence_unreviewed": 5
}